Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Digestive and Liver Disease Année : 2020

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study

(1) , (2) , (3) , (4) , (5) , (6) , (7) , , (8) , (9) , , , , , , , , , ,
1
2
3
4
5
6
7
8
9
Fichier non déposé

Dates et versions

hal-03287294 , version 1 (15-07-2021)

Identifiants

Citer

Violaine Randrian, Antoine Adenis, Jérôme Desrame, Emilie Barbier, Frédéric Di Fiore, et al.. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. Digestive and Liver Disease, 2020, 52 (3), pp.347-350. ⟨10.1016/j.dld.2019.11.014⟩. ⟨hal-03287294⟩
26 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More